Sector: MedicalAlexion Pharmaceuticals, Inc. (NASDAQ: ALXN)
Headlines
- Alexion to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Nov 11, 2009 10:00 AM | ALXN
- Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of Patients With PNH at the ASH Annual Meeting
Nov 10, 2009 06:30 PM | ALXN
- Alexion to Present at Credit Suisse's 2009 Healthcare Conference
Nov 05, 2009 02:47 PM | ALXN
- Alexion to Present at the Oppenheimer 20th Annual Healthcare Conference
Oct 28, 2009 10:35 AM | ALXN
- Alexion to Present at the 20th Annual Healthcare Conference
Oct 28, 2009 10:00 AM | ALXN
- Seven Potential Short Stocks In Healthcare
Oct 26, 2009 09:50 AM | ALXN, BMRN, CPTS, ISRG, LMNX, MASI
- 21 Breakout Stocks To Watch & Using Apple LEAP Options To Generate Income
Oct 23, 2009 04:21 PM | ALXN, AXP, BAC, CAT, FFIV, GE
- Connecticut Technology Council Honors UHY LLP Tech Top 40 Winners
Oct 23, 2009 12:01 AM | ALXN, APH, FCEL, PCLN
- Prix Galien USA to Launch a Health Care Dialogue Among World-Leading Innovators in Science, Economics and Biotech
Sep 22, 2009 01:05 PM | ALXN
- StockPreacher.com Issues Trading Outlook for CEL-SCI Corp
Sep 22, 2009 06:52 AM | ALXN, CVM, IDRA, ZGEN
- Alexion Reports Third Quarter 2009 Results
Oct 22, 2009 06:52 AM | ALXN
- Alexion Pharmaceuticals to Report Third Quarter 2009 Results on October 22, 2009
Oct 12, 2009 10:51 AM | ALXN
- European Commission and U.S. FDA Grant Alexion’s Soliris® (eculizumab) Orphan Drug Designation for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)
Aug 06, 2009 12:02 PM | ALXN
- Alexion Reports Second Quarter 2009 Results
Jul 23, 2009 07:10 AM | ALXN
- BenchmarkJournal.Com Free Analyst Review for QLGC, NEXM, GERN, ENDP, LOGI and ALXN
Jul 21, 2009 10:23 AM | ALXN, ENDP, GERN, LOGI, NEXM, QLGC
- Alexion Pharmaceuticals to Report Second Quarter 2009 Results on July 23, 2009
Jul 09, 2009 10:57 AM | ALXN
- Alexion Extends Its Commitment to a Green Footprint Through Its Ambitious New Solar Energy System
Jun 19, 2009 10:03 AM | ALXN
- Alexion's Soliris® Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease
Jun 10, 2009 01:01 PM | ALXN
- Alexion to Present at the Jefferies & Co. 3rd Annual Healthcare Conference
Jun 10, 2009 10:03 AM | ALXN
- New Research Presented at EHA Congress Shows That Soliris® Significantly Reduced Hemolysis in Never-Transfused Patients with PNH
Jun 07, 2009 05:46 AM | ALXN
- Form 4 BELL LEONARD For: Nov 05 (10K)
Nov 06, 2009 04:08 PM
- Form 4 NORBY R DOUGLAS For: Nov 03 (10K)
Nov 04, 2009 12:09 PM
- Form 4 BELL LEONARD For: Nov 02 (10K)
Nov 03, 2009 05:31 PM
- Form 4 ALEXION PHARMACEUTICALS For: Oct 27 Filed by: MATHIS LARRY (10K)
Oct 27, 2009 03:50 PM
- Form 4 BELL LEONARD For: Oct 12 (10K)
Oct 13, 2009 05:39 PM
- Form 4 BELL LEONARD For: Oct 01 (10K)
Oct 02, 2009 05:37 PM
- Form 4 Sinha Vikas For: Sep 22 (10K)
Sep 22, 2009 05:11 PM
- Form 4 ALEXION PHARMACEUTICALS For: Sep 10 Filed by: LINK MAX (10K)
Sep 14, 2009 04:08 PM
- Form 4 BELL LEONARD For: Sep 01 (10K)
Sep 02, 2009 05:57 PM
- Form 4 SQUINTO STEPHEN P For: Aug 24 (10K)
Aug 26, 2009 04:58 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ALXN
|
Compare to S&P
|
| YTD |
21.30 %
|
0.20 %
|
| 4 Weeks |
-4.61 %
|
-5.11 %
|
| 12 Weeks |
-2.23 %
|
-8.25 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 26.09 %
|
|
EPS Growth in Last Year: 26.09 %
|
|
Sales Growth in Last Quarter: 11.24 %
|
|
Sales Growth in Last Quarter: 34.15 %
|
|
